Medicilon's CEO, Dr. Chunlin Chen was invited to attend the BSK CRO Alliance Forum

The “Cooperation Advantage and Innovative Technology of CRO’s New Drug Development Forum” was held in Nanjing BSK Community on December 5.  The CEO of Medicilon, Dr. Chunlin Chen, was invited to give a speech in the forum.  Dr. Chen gave the speech with the topics “The Concerns of Preclinical Researches of Drugs & Experience Sharing on IND Filing”.

At the meeting, Medicilon and BSK signed the CRO Alliance Cooperation Agreement.  The preclinical services and IND filing of Medicilon have been highly praised and recognized in the industry.  According to the agreement, the companies from the alliance could enjoy the highest quality of CRO services provided by Medicilon in the best price.

BioSciKin Community is led by Simcere Pharmaceutical, supported by government policy and allied with several pharmaceutical companies.  BioSciKin is an open platform for R&D, innovation, investment and incubation for pharmaceutical companies.  Medicilon wishes the BSK platform could help Medicilon to maintain long-term cooperation relationship with more than 40 pharmaceutical enterprises from the CRO Alliance.